Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lyrnphocytic Leukemia (CLL)

被引：0
|
作者：
Brown, Jennifer R.
Harb, Wael A.
Hill, Brian T.
Gabrilove, Janice
Sharman, Jeff P.
Schreeder, Marshall T.
Barr, Paul M.
Foran, James M.
Miller, Thomas P.
Burger, Jan A.
Kelly, Kevin R.
Mahadevan, Daruka
Ma, Shuo
Barnett, Evelyn
Marine, Jeffrey
Nava-Parada, Pilar
Azaryan, Ada
Mei, Jay
Kipps, Thomas J.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1630
引用
收藏
页数：2
相关论文
共 50 条
  • [1] PHASE 1 STUDY OF SINGLE AGENT CC-292, A HIGHLY SELECTIVE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Brown, J. R.
    Harb, W. A.
    Hill, B. T.
    Gabrilove, J.
    Sharman, J. P.
    Schreeder, M. T.
    Barr, P. M.
    Foran, J. M.
    Miller, T. P.
    Burger, J. A.
    Kelly, K. R.
    Mahadevan, D.
    Ma, S.
    Barnett, E.
    Marine, J.
    Nava-Parada, P.
    Azaryan, A.
    Mei, J.
    Kipps, T. J.
    HAEMATOLOGICA, 2014, 99 : 54 - 55
  • [2] Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia
    Brown, Jennifer R.
    Harb, Wael A.
    Hill, Brian T.
    Gabrilove, Janice
    Sharman, Jeff P.
    Schreeder, Marshall T.
    Barr, Paul M.
    Foran, James M.
    Miller, Thomas P.
    Burger, Jan A.
    Kelly, Kevin R.
    Mahadevan, Daruka
    Ma, Shuo
    Li, Yan
    Pierce, Daniel W.
    Barnett, Evelyn
    Marine, Jeffrey
    Miranda, Monika
    Azaryan, Ada
    Yu, Xujie
    Nava-Parada, Pilar
    Mei, Jay
    Kipps, Thomas J.
    HAEMATOLOGICA, 2016, 101 (07) : 295 - 298
  • [3] PHASE 1 STUDY OF SINGLE AGENT CC-292, A HIGHLY SELECTIVE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
    Brown, J.
    Harb, W.
    Sharman, J.
    Hill, B.
    Ma, S.
    Miller, T.
    Schreeder, M.
    Barr, P.
    Foran, J.
    Gabrilove, J.
    Kelly
    Burger, Ja
    Barnett, E.
    Marine, J.
    Nava-Parada, P.
    Azaryan, A.
    Mei, J.
    Kipps, T.
    HAEMATOLOGICA, 2013, 98 : 217 - 217
  • [4] A Chemoproteomics Approach to Determine the Mechanism of Testicular Toxicity for the Bruton's Tyrosine Kinase Inhibitor CC-292
    Labenski, Matt
    Voortman, Lukas
    Medikonda, Aravind Prasad
    Sherratt, Philip J.
    Corin, Alan F.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2021, 379 (02): : 166 - 174
  • [5] THE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR ONO-4059: PROMISING SINGLE AGENT ACTIVITY IN PATIENTS WITH RELAPSED AND REFRACTORY NHL
    Morschhauser, F.
    Terriou, L.
    Dyer, M.
    Hutchinson, C.
    Rule, S.
    Shah, N.
    Salles, G.
    Karlin, L.
    Fegan, C.
    Bagshawe, J.
    Cartron, G.
    Honda, H.
    Nishimura, A.
    Sharpe, J.
    Ohno, T.
    Yoshizawa, T.
    Yasuhiro, T.
    Birkett, J.
    HAEMATOLOGICA, 2014, 99 : 150 - 150
  • [6] Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies
    Cheah, Chan Y.
    Wickham, Nicholas
    Yannakou, Costas K.
    Lewis, Katharine L.
    Hui, Chi-Hung
    Tang, Pek Sang
    Turpuseema, Tejasvi
    Miskin, Hari P.
    Tang, Jian-Ping
    Normant, Emmanuel
    Ricart, Alejandro D.
    Tam, Constantine S.
    BLOOD, 2019, 134
  • [7] Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)
    Woyach, Jennifer A.
    Bojnik, Engin
    Ruppert, Amy S.
    Stefanovski, Matthew R.
    Goettl, Virginia M.
    Smucker, Kelly A.
    Smith, Lisa L.
    Dubovsky, Jason A.
    Towns, William H.
    MacMurray, Jessica
    Harrington, Bonnie K.
    Davis, Melanie E.
    Gobessi, Stefania
    Laurenti, Luca
    Chang, Betty Y.
    Buggy, Joseph J.
    Efremov, Dimitar G.
    Byrd, John C.
    Johnson, Amy J.
    BLOOD, 2014, 123 (08) : 1207 - 1213
  • [8] The Bruton Tyrosine Kinase (Btk) Inhibitor ACP-196: Marked Activity in Relapsed/Refractory CLL with a Favorable Safety Profile
    Byrd, John C.
    Wierda, William
    Jones, Jeffrey
    O'Brien, Susan
    Brown, Jennifer R.
    Schuh, Anna
    Hillmen, Peter
    Stephens, Deborah M.
    Ghia, Paolo
    Devereux, Steve
    Chaves, Jorge M.
    Barrientos, Jacqueline C.
    Wang, Min Hui
    Huang, Jane
    Covey, Todd
    Navarro, Tasheda
    Rothbaum, Wayne
    Izumi, Raquel
    Hamdy, Ahmed
    Furman, Richard R.
    BLOOD, 2015, 126 (23)
  • [9] Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton's Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease
    Ziouti, Fani
    Rummler, Maximilian
    Steyn, Beatrice
    Thiele, Tobias
    Seliger, Anne
    Duda, Georg N.
    Bogen, Bjarne
    Willie, Bettina M.
    Jundt, Franziska
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (08)
  • [10] THE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR IBRUTINIB COMBINED WITH BENDAMUSTINE AND RITUXIMAB IS ACTIVE AND TOLERABLE IN PATIENTS WITH RELAPSED/REFRACTORY CLL, INTERIM RESULTS OF A PHASE IB/II STUDY
    Brown, J.
    Barrientos, J.
    Flinn, I.
    Barr, P.
    Burger, J.
    Navarro, T.
    James, D.
    Hedrick, E.
    Friedberg, J.
    O'Brien, S.
    HAEMATOLOGICA, 2012, 97 : 218 - 218
12345